Drug intelligence / Profile preview

Meningococcal Group A and C Polysaccharide Conjugate Vaccine

Development stage: Phase 3
Lead developer: Serum Institute of India
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This vaccine is used to prevent meningitis caused by serogroups A and C of Neisseria meningitidis. It works by inducing an immune response that protects against these bacterial infections. The vaccine is particularly effective in young children, as it induces a strong immune response and immune memory, which can help eliminate carrier states [1][3].

Brand names: Mening A Con盟纳康
Other names: A群C群脑膜炎球菌多糖结合疫苗Group A and C Meningococcal Conjugate Vaccine

Targets

Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)

Beyond the preview

Go deeper on Meningococcal Group A and C Polysaccharide Conjugate Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meningococcal Group A and C Polysaccharide Conjugate Vaccine.

Explore the full profile